Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 3/20 | 0.32 |
| ▸ | ADH1C | P00326 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22129576 | 1.00 | ALDH1A1 (0.42) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL22129635 | 0.95 | ALDH1A1 (0.39) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL138183 | 0.95 | ALDH1A1 (0.39) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL499430 | 0.94 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL893278 | 0.91 | ALDH1A1 (0.36) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL22129587 | 0.89 | ALDH1A1 (0.42) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL10435134 | 0.89 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL359932 | 0.89 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL27392 | 0.89 | — | — | |
| SCHEMBL893491 | 0.89 | ALDH1A1 (0.42) | ALDH1A1THRBMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4417180-A2 | THERMO-ACTIVE COMPOSITE DENTAL COMPOSITION | VOCO GmbH (DE) | 2024-08-21 | — | — | EP | claimed |
| EP-3810064-B1 | THERMOACTIVE DENTAL COMPOSITE COMPOSITION | VOCO GMBH (DE) | 2024-05-29 | — | — | EP | claimed |
| US-11944692-B2 | Thermoactive dental composite composition | VOCO GMBH (DE) | 2024-04-02 | — | — | US | claimed |
| EP-3810064-A1 | THERMOACTIVE DENTAL COMPOSITE COMPOSITION | VOCO GmbH (DE) | 2021-04-28 | — | — | EP | claimed |
| WO-2019243339-A1 | THERMOACTIVE DENTAL COMPOSITE COMPOSITION | VOCO GMBH (DE) | 2019-12-26 | — | — | WO | claimed |
| EP-1657239-B1 | Chromene compound | TOKUYAMA CORP (JP) | 2010-08-11 | — | — | EP | claimed |
| WO-2026103730-A1 | DIAZAHETEROCYCLIC DERIVATIVE OF PYRIDOARYL GROUP HAVING KAPPA RECEPTOR ANTAGONISTIC ACTIVITY AND COMPOSITION THEREOF, AND USE | 江苏恩华药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20050112409-A1 | Magnetic recording medium | FUJI PHOTO FILM CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| US-20040094753-A1 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6723859-B2 | BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES | TOKUYAMA CORPORATION (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1394156-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20040014995-A1 | Chromene compounds | KAWABATA YUICHIRO (JP) | 2004-01-22 | — | — | US | disclosed |
| US-20030096117-A1 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1184379-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | ALDH1A1 3619/4885THRB 953/4885MEN1 3442/4885 |
| US-20040014995-A1 | Chromene compounds | SMARCE1, SMARCB1, SMARCA2 | ALDH1A1 2905/4885THRB 4750/4885MEN1 2481/4885 |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | ALDH1A1 1035/4885THRB 964/4885MEN1 3740/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | ALDH1A1 100/4885THRB 995/4885MEN1 1978/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | ALDH1A1 2041/4885THRB 2558/4885MEN1 3638/4885 |
| US-20030096117-A1 | Chromene compound | SMARCE1, SMARCD2, SMARCB1 | ALDH1A1 3101/4885THRB 4732/4885MEN1 2413/4885 |
| US-11944692-B2 | Thermoactive dental composite composition | PUF60, POLQ, F10 | ALDH1A1 1414/4885THRB 4503/4885MEN1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.